Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Issuing a so-called positive opinion, EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Kaftrio as a combination therapy for CF patients aged two years and older with a ...
The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.
The pharmaceutical industry with blockbuster drug potential represents a high-growth opportunity for investors seeking transformative returns. These companies invest heavily in research and ...
A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey towards seeing this treatment in the clinic. For this first phase, the ...
Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...